DK3442513T3 - Anvendelse af cannabidiolsyre i behandling af autismespektrumforstyrrelse og forbundne forstyrrelser - Google Patents
Anvendelse af cannabidiolsyre i behandling af autismespektrumforstyrrelse og forbundne forstyrrelser Download PDFInfo
- Publication number
- DK3442513T3 DK3442513T3 DK17718582.4T DK17718582T DK3442513T3 DK 3442513 T3 DK3442513 T3 DK 3442513T3 DK 17718582 T DK17718582 T DK 17718582T DK 3442513 T3 DK3442513 T3 DK 3442513T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- autism spectrum
- associated disorders
- spectrum disorder
- cannabidiolic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/348—Cannabaceae
- A61K36/3482—Cannabis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1606097.2A GB2549277B (en) | 2016-04-11 | 2016-04-11 | Cannabidiolic Acid for use in the Treatment of Autism Spectrum Disorder |
| PCT/GB2017/051010 WO2017178810A1 (en) | 2016-04-11 | 2017-04-11 | Use of cannabidiolic acid in the treatment of autism spectrum disorder and associated disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3442513T3 true DK3442513T3 (da) | 2021-09-06 |
Family
ID=58579205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17718582.4T DK3442513T3 (da) | 2016-04-11 | 2017-04-11 | Anvendelse af cannabidiolsyre i behandling af autismespektrumforstyrrelse og forbundne forstyrrelser |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10898462B2 (da) |
| EP (2) | EP3970706A1 (da) |
| AU (1) | AU2017251607B2 (da) |
| CA (1) | CA3020528A1 (da) |
| DK (1) | DK3442513T3 (da) |
| ES (1) | ES2886451T3 (da) |
| GB (1) | GB2549277B (da) |
| NZ (1) | NZ748016A (da) |
| WO (1) | WO2017178810A1 (da) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2992838T3 (en) | 2017-09-28 | 2024-12-18 | Harmony Biosciences Man Inc | Treatment of irritability in autism spectrum disorder with cannabidiol |
| MX2020010603A (es) | 2018-04-09 | 2021-02-02 | Ellevet Sciences | Extracto de cáñamo para tratamiento de dolor en animales. |
| KR20210104084A (ko) | 2018-12-14 | 2021-08-24 | 지네르바 파마슈티컬스, 인코포레이티드 | 칸나비디올을 사용하는 22q11.2 결실 증후군의 치료 |
| EP4157236A1 (en) * | 2020-05-26 | 2023-04-05 | Zynerba Pharmaceuticals, Inc. | Treatment of autism spectrum disorder with cannabidiol |
| BR112022026044A2 (pt) * | 2020-06-29 | 2023-03-07 | Zynerba Pharmaceuticals Inc | Tratamento de síndrome do x frágil com canabidiol |
| JP2023545511A (ja) * | 2020-10-17 | 2023-10-30 | デイビッド アンダーソン | オリベトール酸誘導体の製剤および非共有結合性安定化 |
| WO2022254338A1 (en) * | 2021-06-04 | 2022-12-08 | Buzzelet Development And Technologies Ltd. | Compositions and methods for treating epilepsy and/or autism |
| WO2023043197A1 (ko) * | 2021-09-15 | 2023-03-23 | 강원대학교 산학협력단 | 신규한 카나비디올 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물 |
| JP2024536075A (ja) * | 2021-10-11 | 2024-10-04 | ニューロテック インターナショナル リミテッド | 神経障害を処置するための組成物および方法 |
| IL311854A (en) * | 2021-10-11 | 2024-05-01 | Neurotech Int Ltd | Preparations and methods for the treatment of neurological disorders with combination products |
| US12440454B2 (en) | 2022-02-01 | 2025-10-14 | Portland Technology Holdings Llc | Pharmaceutical compositions containing hemp extract for administration to felines and related methods |
| WO2024073812A1 (en) * | 2022-10-06 | 2024-04-11 | Neurotech International Ltd | Methods for treating paediatric neurological disorders |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7629123B2 (en) * | 2003-07-03 | 2009-12-08 | University Of Medicine And Dentistry Of New Jersey | Compositions and methods for diagnosing autism |
| WO2006017892A1 (en) * | 2004-08-16 | 2006-02-23 | Northern Sydney And Central Coast Area Health Service | Methods for improving cognitive functioning |
| GB2434312B (en) * | 2006-01-18 | 2011-06-29 | Gw Pharma Ltd | Cannabinoid-containing plant extracts as neuroprotective agents |
| GB2438682A (en) | 2006-06-01 | 2007-12-05 | Gw Pharma Ltd | New use for cannabinoids |
| EP2341903A1 (en) * | 2008-07-31 | 2011-07-13 | Bionorica Research GmbH | Cannabinoids for use in treating or preventing cognitive impairment and dementia |
| RS60295B1 (sr) | 2013-03-19 | 2020-07-31 | Univ Pompeu-Fabra | Antagonisti kanabionoidnih receptora cb1 za upotrebu u lečenju oboljenja vezanih za abnormalnosti neuronskih dendrita |
| AU2015266897B2 (en) * | 2014-05-29 | 2020-07-30 | Fresh Cut Development, Llc | Stable cannabinoid formulations |
| CN107205960A (zh) * | 2014-10-21 | 2017-09-26 | 联合大麻公司 | 大麻提取物及其制备和使用方法 |
| CA2966710A1 (en) * | 2014-11-03 | 2016-05-12 | Ramot At Tel Aviv University Ltd. | Methods for treatment of cognitive decline |
| AU2016226267A1 (en) * | 2015-03-02 | 2017-09-28 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with cannabinoids |
-
2016
- 2016-04-11 GB GB1606097.2A patent/GB2549277B/en active Active
-
2017
- 2017-04-11 US US16/092,560 patent/US10898462B2/en active Active
- 2017-04-11 AU AU2017251607A patent/AU2017251607B2/en not_active Ceased
- 2017-04-11 ES ES17718582T patent/ES2886451T3/es active Active
- 2017-04-11 NZ NZ748016A patent/NZ748016A/en not_active IP Right Cessation
- 2017-04-11 WO PCT/GB2017/051010 patent/WO2017178810A1/en not_active Ceased
- 2017-04-11 EP EP21190539.3A patent/EP3970706A1/en not_active Withdrawn
- 2017-04-11 DK DK17718582.4T patent/DK3442513T3/da active
- 2017-04-11 EP EP17718582.4A patent/EP3442513B1/en active Active
- 2017-04-11 CA CA3020528A patent/CA3020528A1/en active Pending
-
2020
- 2020-12-21 US US17/128,458 patent/US12150927B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US12150927B2 (en) | 2024-11-26 |
| CA3020528A1 (en) | 2017-10-19 |
| AU2017251607B2 (en) | 2023-02-23 |
| EP3970706A1 (en) | 2022-03-23 |
| AU2017251607A1 (en) | 2018-11-29 |
| US10898462B2 (en) | 2021-01-26 |
| ES2886451T3 (es) | 2021-12-20 |
| NZ748016A (en) | 2023-04-28 |
| US20190117619A1 (en) | 2019-04-25 |
| EP3442513A1 (en) | 2019-02-20 |
| GB2549277B (en) | 2021-02-17 |
| GB2549277A (en) | 2017-10-18 |
| US20210205262A1 (en) | 2021-07-08 |
| WO2017178810A1 (en) | 2017-10-19 |
| EP3442513B1 (en) | 2021-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279752B (en) | Polycyclic compounds and use thereof in the treatment of immune disorders | |
| DK3442513T3 (da) | Anvendelse af cannabidiolsyre i behandling af autismespektrumforstyrrelse og forbundne forstyrrelser | |
| DK3334422T3 (da) | Anvendelse af cannabidiolsyre i behandling af epilepsi | |
| IL263484A (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
| DK3277815T3 (da) | Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser | |
| DK3882250T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser | |
| HUE054548T2 (hu) | Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében | |
| EP3359171C0 (en) | Use of akkermansia muciniphila for treating inflammatory conditions | |
| PL3157512T3 (pl) | Zastosowanie kannabidioli w leczeniu padaczki | |
| DK3185876T3 (da) | Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser | |
| DK3297644T3 (da) | Fremgangsmåder til behandling af autismespektrumforstyrrelse og forbundne symptomer | |
| DK3215511T3 (da) | Substituerede pyrazolo(1,5-a)pyrimidiner og deres anvendelse i behandlingen af medicinske lidelser | |
| GB2542155B (en) | Use of cannabidiol in the treatment of mental disorders | |
| HUE050095T2 (hu) | Anyagcsere-rendellenességek kezelése lófélékben | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| PL3503890T3 (pl) | Stosowanie pridopidyny w leczeniu dystonii | |
| EP3334429C0 (en) | HYPERPHENYLALANINEMIA AND TREATMENTS THEREFOR | |
| DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
| DK3439663T3 (da) | Fremgangsmåder til behandling af pædiatriske cancere | |
| DK3273995T3 (da) | Kombineret anvendelse af alginatoligomerer og cftr-modulatoren lumacaftor i behandlingen af tilstande associeret med cftr-dysfunktion | |
| DK3442547T3 (da) | Lactobacillus reuteri MM4-1A til anvendelse i behandling eller forebyggelse af autismespektrumforstyrrelser | |
| DK3149049T3 (da) | Il-22 til anvendelse til behandling af stofskiftesygdomme | |
| DK3722291T3 (da) | Indolinonforbindelser og deres anvendelse i behandlingen af fibrotiske sygdomme | |
| DK3551166T3 (da) | Topisk phenytoin til anvendelse i behandling af periferisk neuropatisk smerte | |
| DK3373922T3 (da) | Sammensætninger og fremgangsmåder til anvendelse i behandlingen af homocystinuri |